Single-fraction or multi-fraction stereotactic ablative body radiotherapy followed by atezolizumab in advanced triple-negative breast cancer: a randomized phase II trial.
- DOI
- 10.1038/s41467-026-75660-y
- Published
- 2026 Jul 27
- Container
- Nature communications
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1038/s41467-026-75660-y,
title = {Single-fraction or multi-fraction stereotactic ablative body radiotherapy followed by atezolizumab in advanced triple-negative breast cancer: a randomized phase II trial.},
author = {David S and Savas P and Siva S and Bressel M and White M and Nikolic B and Neeson MW and White S and Marx G and Cheuk R and Grogan M and Farrell M and Foudoulis J and Neeson PJ and Loi S},
year = {2026},
journal = {Nature communications},
doi = {10.1038/s41467-026-75660-y},
url = {https://doi.org/10.1038/s41467-026-75660-y}
}RIS
TY - JOUR TI - Single-fraction or multi-fraction stereotactic ablative body radiotherapy followed by atezolizumab in advanced triple-negative breast cancer: a randomized phase II trial. AU - David S AU - Savas P AU - Siva S AU - Bressel M AU - White M AU - Nikolic B AU - Neeson MW AU - White S AU - Marx G AU - Cheuk R AU - Grogan M AU - Farrell M AU - Foudoulis J AU - Neeson PJ AU - Loi S PY - 2026 JO - Nature communications DO - 10.1038/s41467-026-75660-y UR - https://doi.org/10.1038/s41467-026-75660-y ER -
APA
S, D., P, S., S, S., M, B., M, W., B, N., MW, N., S, W., G, M., R, C., M, G., M, F., J, F., PJ, N., & S, L. (2026). Single-fraction or multi-fraction stereotactic ablative body radiotherapy followed by atezolizumab in advanced triple-negative breast cancer: a randomized phase II trial.. Nature communications. https://doi.org/10.1038/s41467-026-75660-y
Source records
- pubmed · retrieved 2026-09-26T05:52:30.543Z